



# Resource impact template

Resource impact

Published: 22 December 2025

[www.nice.org.uk](http://www.nice.org.uk)

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for primary advanced or recurrent endometrial cancer:

- [Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency](#) (2025) NICE technology appraisal guidance 1117
- [Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer](#) (2025) NICE technology appraisal guidance 1092
- [Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency](#) (2025) NICE technology appraisal guidance 1064